Constellium downgraded to Neutral from Overweight at JPMorgan

JPMorgan downgraded Constellium (CSTM) to Neutral from Overweight with a price target of $34, up from $30. The company’s 2027 growth is likely to be partly offset by scrap spread compression and less benefit from the active braking safety share gains in 2026, the analyst tells investors in a research note. The firm also believes Constellium’s near-term demand remains challenged across certain end markets in both the U.S. and Europe.